Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Trial Timeline
Apr 1, 2016 → Mar 22, 2024
NCT ID
NCT02754726About Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine
Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine is a phase 2 stage product being developed by Bristol Myers Squibb for Untreated Metastatic Pancreatic Ductal Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02754726. Target conditions include Untreated Metastatic Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
1 of 4 similar drugs in Untreated Metastatic Pancreatic Ductal Adenocarcinoma were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02754726 | Phase 2 | Completed |
Competing Products
15 competing products in Untreated Metastatic Pancreatic Ductal Adenocarcinoma